Do analysts recommend AQST or MENS?

Aquestive Therapeutics presently has a consensus target price of $8.60, indicating a potential upside of 79.92%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, AQST or MENS?

Jyong Biotech has lower revenue, but higher earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aquestive Therapeutics $44.54M 13.47 -$83.78M -$0.65 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is AQST or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -144.63% N/A -52.40% Jyong Biotech N/A N/A N/A

Do analysts recommend CRMD or MENS?

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 103.25%. Given CorMedix's stronger consensus rating and higher probable upside, equities research analysts clearly believe CorMedix is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CRMD or MENS?

CorMedix has higher revenue and earnings than Jyong Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $457.20M 1.26 $163.05M $2.14 3.45 Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts rate PHAT or MENS?

Phathom Pharmaceuticals presently has a consensus price target of $21.25, suggesting a potential upside of 193.10%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, PHAT or MENS?

Jyong Biotech has lower revenue, but higher earnings than Phathom Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phathom Pharmaceuticals $175.11M 3.35 -$221.25M -$1.28 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is PHAT or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -41.34% N/A -20.81% Jyong Biotech N/A N/A N/A

Do analysts rate TLRY or MENS?

Tilray Brands presently has a consensus target price of $5.90, indicating a potential upside of 66.67%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.38 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, TLRY or MENS?

Jyong Biotech has lower revenue, but higher earnings than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tilray Brands $915.45M 0.53 -$121.40M -$1.08 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts rate MENS or OCS?

Oculis has a consensus price target of $39.44, suggesting a potential upside of 372.95%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has stronger valuation and earnings, MENS or OCS?

Jyong Biotech has higher earnings, but lower revenue than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Oculis $1.45M 333.48 -$119.44M -$1.74 N/A

Is MENS or OCS more profitable?

Jyong Biotech has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Jyong Biotech's return on equity of 0.00% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Oculis -6,777.18% -42.61% -35.23%

Jyong Biotech (MENS) Competitors

$2.10 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 -0.02 (-1.19%)

As of 07:30 PM Eastern

Compare

MENS vs. AQST, CRMD, PHAT, TLRY, and OCS

Should you buy Jyong Biotech stock or one of its competitors? Jyong Biotech's main competitors and comparable companies include Aquestive Therapeutics (AQST), CorMedix (CRMD), Phathom Pharmaceuticals (PHAT), Tilray Brands (TLRY), and Oculis (OCS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jyong Biotech compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

In the previous week, Aquestive Therapeutics had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Aquestive Therapeutics and 1 mentions for Jyong Biotech. Aquestive Therapeutics' average media sentiment score of 0.45 beat Jyong Biotech's score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Neutral
Jyong Biotech	Neutral

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Jyong Biotech has lower revenue, but higher earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	13.47	-$83.78M	-$0.65	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Jyong Biotech	N/A	N/A	N/A

Aquestive Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

Aquestive Therapeutics presently has a consensus target price of $8.60, indicating a potential upside of 79.92%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aquestive Therapeutics beats Jyong Biotech on 9 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, CorMedix had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for CorMedix and 1 mentions for Jyong Biotech. CorMedix's average media sentiment score of 0.83 beat Jyong Biotech's score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Jyong Biotech	Neutral

34.2% of CorMedix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 103.25%. Given CorMedix's stronger consensus rating and higher probable upside, equities research analysts clearly believe CorMedix is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CorMedix has a net margin of 40.49% compared to Jyong Biotech's net margin of 0.00%. CorMedix's return on equity of 40.52% beat Jyong Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Jyong Biotech	N/A	N/A	N/A

CorMedix has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

CorMedix has higher revenue and earnings than Jyong Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.26	$163.05M	$2.14	3.45
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Summary

CorMedix beats Jyong Biotech on 12 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Phathom Pharmaceuticals had 4 more articles in the media than Jyong Biotech. MarketBeat recorded 5 mentions for Phathom Pharmaceuticals and 1 mentions for Jyong Biotech. Phathom Pharmaceuticals' average media sentiment score of 0.28 beat Jyong Biotech's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Jyong Biotech	Neutral

Jyong Biotech has lower revenue, but higher earnings than Phathom Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.35	-$221.25M	-$1.28	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Phathom Pharmaceuticals presently has a consensus price target of $21.25, suggesting a potential upside of 193.10%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Jyong Biotech	N/A	N/A	N/A

Phathom Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Jyong Biotech on 9 of the 13 factors compared between the two stocks.

How does Jyong Biotech compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

9.4% of Tilray Brands shares are held by institutional investors. 1.6% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tilray Brands has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

In the previous week, Tilray Brands had 36 more articles in the media than Jyong Biotech. MarketBeat recorded 37 mentions for Tilray Brands and 1 mentions for Jyong Biotech. Tilray Brands' average media sentiment score of 0.29 beat Jyong Biotech's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Tilray Brands	Neutral
Jyong Biotech	Neutral

Tilray Brands presently has a consensus target price of $5.90, indicating a potential upside of 66.67%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.38
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has a net margin of 0.00% compared to Tilray Brands' net margin of -16.91%. Jyong Biotech's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-16.91%	-10.47%	-7.52%
Jyong Biotech	N/A	N/A	N/A

Jyong Biotech has lower revenue, but higher earnings than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45M	0.53	-$121.40M	-$1.08	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Summary

Tilray Brands beats Jyong Biotech on 9 of the 14 factors compared between the two stocks.

How does Jyong Biotech compare to Oculis?

Jyong Biotech (NASDAQ:MENS) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Jyong Biotech has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Oculis has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Oculis has a consensus price target of $39.44, suggesting a potential upside of 372.95%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Oculis had 5 more articles in the media than Jyong Biotech. MarketBeat recorded 6 mentions for Oculis and 1 mentions for Jyong Biotech. Oculis' average media sentiment score of 0.37 beat Jyong Biotech's score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Oculis	Neutral

Jyong Biotech has higher earnings, but lower revenue than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Oculis	$1.45M	333.48	-$119.44M	-$1.74	N/A

Jyong Biotech has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Jyong Biotech's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Oculis	-6,777.18%	-42.61%	-35.23%

22.3% of Oculis shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Oculis beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

Get Jyong Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MENS vs. The Competition

Export

Metric	Jyong Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$159.66M	$12.34B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	20.71%
P/E Ratio	N/A	797.58	274.13	26.16
Price / Sales	N/A	754.39	589.97	95.24
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-6.36	10.71	11.21	6.34
Net Income	-$4.67M	$2.84B	$3.50B	$381.90M
7 Day Performance	-3.67%	-0.99%	-0.84%	-1.39%
1 Month Performance	-2.78%	-5.86%	-5.42%	-4.31%
1 Year Performance	-96.12%	-5.32%	4.38%	-0.35%

Jyong Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MENS Jyong Biotech	N/A	$2.10 flat	N/A	-95.9%	$159.66M	N/A	N/A	27
AQST Aquestive Therapeutics	1.7905 of 5 stars	$4.61 +0.9%	$9.17 +98.8%	-23.2%	$578.61M	$54.09M	N/A	147	Positive News
CRMD CorMedix	2.8832 of 5 stars	$7.28 +0.3%	$15.00 +106.0%	-35.0%	$567.40M	$311.71M	3.40	191	Analyst Upgrade
PHAT Phathom Pharmaceuticals	3.0427 of 5 stars	$6.78 +1.2%	$21.25 +213.4%	-35.5%	$548.51M	$239.66M	N/A	371
TLRY Tilray Brands	4.19 of 5 stars	$3.78 +1.6%	$6.38 +68.7%	-79.1%	$514.85M	$210.48M	N/A	3,595	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MENS) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jyong Biotech (MENS) Competitors

MENS vs. AQST, CRMD, PHAT, TLRY, and OCS

How does Jyong Biotech compare to Aquestive Therapeutics?

Summary

How does Jyong Biotech compare to CorMedix?

Summary

How does Jyong Biotech compare to Phathom Pharmaceuticals?

Summary

How does Jyong Biotech compare to Tilray Brands?

Summary

How does Jyong Biotech compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jyong Biotech (MENS) Competitors

MENS vs. AQST, CRMD, PHAT, TLRY, and OCS

How does Jyong Biotech compare to Aquestive Therapeutics?

Does the media favor AQST or MENS?

Do insiders and institutionals believe in AQST or MENS?

Which has better valuation & earnings, AQST or MENS?

Is AQST or MENS more profitable?

Which has more risk & volatility, AQST or MENS?

Do analysts recommend AQST or MENS?

Summary

How does Jyong Biotech compare to CorMedix?

Does the media prefer CRMD or MENS?

Do insiders & institutionals hold more shares of CRMD or MENS?

Do analysts recommend CRMD or MENS?

Is CRMD or MENS more profitable?

Which has more volatility and risk, CRMD or MENS?

Which has better earnings & valuation, CRMD or MENS?

Summary

How does Jyong Biotech compare to Phathom Pharmaceuticals?

Do institutionals & insiders hold more shares of PHAT or MENS?

Does the media refer more to PHAT or MENS?

Which has stronger valuation & earnings, PHAT or MENS?

Do analysts rate PHAT or MENS?

Is PHAT or MENS more profitable?

Which has more risk & volatility, PHAT or MENS?

Summary

How does Jyong Biotech compare to Tilray Brands?

Do institutionals & insiders believe in TLRY or MENS?

Which has more volatility and risk, TLRY or MENS?

Does the media favor TLRY or MENS?

Do analysts rate TLRY or MENS?

Is TLRY or MENS more profitable?

Which has better valuation & earnings, TLRY or MENS?

Summary

How does Jyong Biotech compare to Oculis?

Which has more risk & volatility, MENS or OCS?

Do analysts rate MENS or OCS?

Does the media refer more to MENS or OCS?

Which has stronger valuation and earnings, MENS or OCS?

Is MENS or OCS more profitable?

Do insiders & institutionals have more ownership in MENS or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MENS vs. The Competition

Jyong Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools